Latest Impairment Charges News

Big River Industries reported a modest revenue decline in FY25 but achieved improved margins and operational efficiencies in the second half, positioning itself for growth as market conditions begin to stabilise.

Big River Industries reported a statutory net loss of $14.7 million for FY2025, driven by a $20 million impairment charge on intangible assets amid a 2.3% revenue decline. Despite the setback, the company declared a fully franked 2 cent dividend and showed signs of operational stabilization.

Viva Energy reported a statutory half-year loss of $195.4 million driven by significant retail site impairments and weak refining margins, yet underlying profit on a replacement cost basis remained positive at $62.6 million. The company declared a fully franked interim dividend of 2.83 cents per share, signaling confidence despite operational headwinds.

Noumi Limited reported modest revenue growth and a significant rise in adjusted EBITDA for FY25, driven by its Milklab brand’s strong performance and a continued turnaround in its Dairy & Nutritionals segment. The company also resolved all legacy legal issues, positioning itself for future growth.

Noumi Limited has posted a significant $150 million loss for the year ending June 2025, driven by non-cash charges and raising questions about its financial stability.

Genetic Signatures reported a 63% revenue increase to $15.9 million in FY25, alongside a 28% reduction in underlying losses and a strategic shift in its automated diagnostics platform development.

Genetic Signatures Limited reported a 63% revenue surge to $15.9 million in FY25, driven by strong Australian sales and progress in EMEA, while navigating a $20.1 million net loss and a strategic pivot towards partnerships for automated diagnostics.

Bendigo and Adelaide Bank reported an 11% rise in customers and a 6.6% increase in deposits for FY25, while statutory earnings were weighed down by a significant goodwill impairment charge.

International Equities Corporation Ltd reported a $1.249 million net loss for FY2025, reflecting ongoing challenges in its tourism segment amid a slowing economy and rising costs. The company’s property development and leasing operations also faced headwinds, leading to a decline in overall revenue and asset backing.

Healius Limited reported a 5.7% rise in FY25 revenue driven by pathology growth, while underlying EBIT fell 27% impacted by cyclone disruptions and restructuring. The company advances its pathology strategy and cost savings post-Lumus divestment.

Healius reported a 5.7% rise in FY25 revenue with underlying EBIT meeting consensus, buoyed by strong pathology growth and a significant profit from the Lumus Imaging sale. Despite challenges at Agilex Biolabs and a major goodwill impairment, the company targets improved margins by 2027.

Universal Store Holdings Limited reported a robust FY25 with sales rising 15.5% to $333.3 million and underlying EBIT up 15.9%, driven by strong performances across its retail brands and disciplined cost management.